Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 300.0% in April

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 12,000 shares, an increase of 300.0% from the March 31st total of 3,000 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average daily volume of 73,000 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Virax Biolabs Group stock. Armistice Capital LLC purchased a new position in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 121,999 shares of the company’s stock, valued at approximately $178,000. Armistice Capital LLC owned about 7.87% of Virax Biolabs Group as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 8.61% of the company’s stock.

Virax Biolabs Group Stock Performance

Virax Biolabs Group stock opened at $0.69 on Friday. Virax Biolabs Group has a fifty-two week low of $0.61 and a fifty-two week high of $5.45. The firm’s 50-day simple moving average is $0.81 and its 200 day simple moving average is $1.45.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.